GlassScriptPhysician profile
Muhammad T Sarmini
NPI 1366706590
$1,891.71
in general payments reported to CMS, 2019-2025
23 companies · $553 in 2025
The $553 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $99.00 · 2021: $62.21 · 2022: $63.86 · 2023: $436 · 2024: $677 · 2025: $553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,667.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,666.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $538.55 | 2023-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $259.90 | 2020-2025 | Stelara, Tremfya |
| Madrigal Pharmaceuticals | $211.86 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $111.55 | 2023 | Sucraid |
| Pfizer INC. | $109.63 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $106.92 | 2022-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $79.18 | 2021-2024 | Xifaxan, Trulance |
| Celgene Corporation | $59.01 | 2023-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $47.53 | 2023-2024 | Dupixent |
| Aimmune Therapeutics, INC. | $46.49 | 2024-2025 | Zenpep |
| Ardelyx, INC. | $42.05 | 2023-2024 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $39.33 | 2023 | |
| Phathom Pharmaceuticals, INC. | $32.71 | 2025 | Voquezna |
| Vibrant Gastro, INC. | $31.32 | 2024 | Vibrant Starter Kit |
| Genzyme Corporation | $27.93 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $27.67 | 2025 | Omvoh |
| Laborie Medical Technologies Corp. | $23.72 | 2024 | |
| Organon LLC | $18.61 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.13 | 2023 | Cyltezo |
| Medtronic, INC. | $16.29 | 2024 | Gi Genius |
| Merck Sharp & Dohme LLC | $15.82 | 2023 | Dificid |
| Celltrion USA INC. | $14.39 | 2024 | Vegzelma |
| Braintree Laboratories, INC. | $13.12 | 2024 | Suflave, Sutab |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Sarmini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.